Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne

Foamix and Taro Enter License Agreement for the Development and Commercialization of Foamix's PerFoam™ 1% for the Treatment of Head Lice

Globes: Foamix displays its wares

Foamix Announces New Waterless Foam Designed for Enhanced Skin Delivery - Useful for Steroids and Water Sensitive Drugs

Foamix’s Betamethasone Foam Demonstrates High Efficacy in Psoriasis Treatment and 85% Better Usability than Cream in Phase I/II Study

Foamix Names David Schuz as Senior Vice President, Intellectual Property

Foamix foam technology is featured in Ynet Health (Hebrew)

Foamix featured among finalists by AICC Eagle Star Awards for Deal of the Year

Foamix LTD is featured in Bioexecutive International, March 2006

Foamix CEO to Present “The Changing Face of Dermatology” at the Bio Business Forum at Bio International 2006 in Chicago, April 10, 2006

Foamix is featured in a news package about the thriving Israeli biotech scene, produced by FBC Media and broadcast globally on World Business

Live interview with Foamix Executive Director Dr. Stanley Hirsch on Duke and the Doctor, a radio program broadcast on 150 stations in the U.S. Dr. Hirsch discusses the benefits of foam and the Company’s plans for the future.

Foamix Receives Patents for OilGel™ In the U.S. and in Australia

Cosmeticsdesign.com: Foamix granted US patent for OilGel

LEO and Foamix to Develop Two New Medicated Foams for the Treatment of Psoriasis.

Foamix Granted Third U.S. Patent for OilGel™, In Development for Dermatological and Ophthalmic Applications.

Foamix Executive Director Dr. Stanley Hirsch to Present “Foamix - Innovative Delivery in Dermatology” at Bio-Europe 2005, November 8th at 8:30 a.m.

New Foam Product for the Treatment of Scabies: A Development Collaboration by Stiefel Laboratories, Inc. of the USA and Foamix Ltd. of Israel

Foamix to Showcase Emulsion-Based Cosmetic Foams at The Health and Beauty America (HBA) Conference in New York

Drug Topics: Are new lice treatments up to scratch?

Globes: Foamix lice treatment demonstrates 96% efficacy in Phase II/III study

Foamix’s PerFoam™ for the Treatment of Lice Demonstrates Safety and 96% Efficacy in Phase II/III Study

In-Pharma Technologist.com: Topical drug delivery gel patented by Foamix

Foamix Selected to Present at the Bio Business Forum at Bio International 2005 in Philadelphia in June

Israel 21C: Foam - the Israeli way to take the sting out of skin treatments

MarketWatch: Israel's Foamix eyes U.S. IPO in next 18 months

Globes article: Drug Delivery Technology co Foamix raising $5m

Foamix "Breaks the Ribbon" on New Facility

Foamix Unveils Unique Mupirocin Foam

Foamix Unveils Innovative Vaginal Foam

Frost & Sullivan alert : A new trend in dermatological drug delivery: foamy carriers

Phase II Psoriasis Study Approved

 

Foamix Names David Schuz as Senior Vice President, Intellectual Property


The appointment supports Foamix’s growth and expanding intellectual property portfolio

Ness Ziona, Israel, July 17, 2006 ---- Foamix, a specialty pharmaceutical company that develops innovative dermatology foam and OilGel™ products, announced today the appointment of David Schuz as Senior Vice President, Intellectual Property. Mr. Schuz will be primarily responsible for managing IP affairs including Foamix’s expanding patent and trademark portfolio as well as directing IP strategy and IP due diligence.

“I am delighted to join the management team and look forward to exciting times to come,” said Mr. Schuz.

Mr. Schuz joins Foamix from Bio-Technology General (Israel) Ltd. where he served as Vice President, Legal. He also served at various times as Acting General Counsel, Associate General Counsel, Senior Director and Head of IP Worldwide at Savient Pharmaceuticals Inc., the company from which Bio-Technology General (Israel) Ltd. was divested in 2005. From 1984 to 1999, Mr. Schuz held legal and intellectual property positions at S. Horovitz & Co., Advocates and Patent Attorneys, at Dr. Reinhold Cohn and Partners, Patent Attorneys, as well as at Raymond Saul & Co., Solicitors. He also lectured on patent issues at the Faculty of Law at Bar Ilan University, from 1996-2001.

“From its inception, Foamix has been built on a solid foundation of strong IP. However, in the last year, our patent portfolio has broadened extensively and considerably. This is the reason for inviting Mr. Schuz to join our team. Foamix has graduated to a new league and intends to maintain its leadership pace in the creation of new pharmaceutical and cosmeceutical foam and OilGel™ products,” said Foamix CEO Dr. Dov Tamarkin.

Mr. Schuz acquired his legal and intellectual property education at LSE, University of London, QMW, University of London and the University of Trent, Nottingham, UK. He also holds an M. Phil. Degree in Biochemistry and a Diploma of Pharmacology from the University of Cambridge.

“Foamix has a technology and a business model unmatched anywhere. The Company has a robust and growing product pipeline, born out of a steady stream of IP. Foamix continues to strengthen its position in the market by establishing partnerships with leading pharmaceutical companies. Our IP portfolio is an attractive asset to our partners as it protects innovation and lifecycle management. Mr. Schuz is an astute and highly talented attorney, whose wealth of experience is certain to benefit Foamix and its partners,” said Foamix COO Mr. Meir Eini.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, non-flammable, stable foam and OilGelŪ products for prescription, Over-the-Counter and cosmetic uses. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. The Company’s development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical trials and clinical studies. The Company was founded in January 2003 by CEO Dr. Dov Tamarkin, COO Mr. Meir Eini and Chief Technology Officer Dr. Doron Friedman. Foamix Ltd. is a privately held company, whose business model is based on partnering with leading pharma and cosmetics companies to develop products utilizing its proprietary foam and OilGel™ technologies. .

For additional information: www.foamix.co.il or Marjie Hadad, Media Liaison, Foamix, Marjie@foamix.co.il; +972-54-536-5220.